EU/3/05/320

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in April 2012 on request of the sponsor.

On 28 October 2005, orphan designation (EU/3/05/320) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of chronic eosinophilic leukaemia and hypereosinophilic syndrome.

Imatinib mesilate for treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome has been authorised in the EU as Glivec since 28 November 2006.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
imatinib mesilate
Medicine name
Glivec
Disease / condition
Treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome
Date of first decision
28/10/2005
Outcome
Expired
EU designation number
EU/3/05/320

Sponsor's contact details

Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 61 324 11 11 (Switzerland)
E-mail: orphan.enquiries@novartis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating